MA37808A1 - Composés et leurs utilisations thérapeutiques - Google Patents
Composés et leurs utilisations thérapeutiquesInfo
- Publication number
- MA37808A1 MA37808A1 MA37808A MA37808A MA37808A1 MA 37808 A1 MA37808 A1 MA 37808A1 MA 37808 A MA37808 A MA 37808A MA 37808 A MA37808 A MA 37808A MA 37808 A1 MA37808 A1 MA 37808A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- therapeutic uses
- ischemia
- obesity
- lymphocytes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/58—Amidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
La présente invention concerne des composés, des compositions pharmaceutiques et des méthodes utiles dans le traitement du cancer, de l'inflammation systémique ou chronique, de l'arthrite rhumatoïde, du diabète, de l'obésité, de la maladie auto-immune à médiation par lymphocytes t, de l'ischémie, et d'autres complications associées à ces maladies et à ces troubles.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261665297P | 2012-06-27 | 2012-06-27 | |
PCT/US2013/048274 WO2014004884A1 (fr) | 2012-06-27 | 2013-06-27 | Composés et leurs utilisations thérapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA37808A1 true MA37808A1 (fr) | 2018-03-30 |
Family
ID=49783870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37808A MA37808A1 (fr) | 2012-06-27 | 2013-06-27 | Composés et leurs utilisations thérapeutiques |
Country Status (16)
Country | Link |
---|---|
US (1) | US20150344426A1 (fr) |
EP (1) | EP2867209A4 (fr) |
JP (1) | JP2015522028A (fr) |
KR (1) | KR20150024932A (fr) |
CN (1) | CN104768931A (fr) |
AU (1) | AU2013284487A1 (fr) |
BR (1) | BR112014032917A2 (fr) |
CL (1) | CL2014003560A1 (fr) |
IL (1) | IL236499A0 (fr) |
IN (1) | IN2015KN00240A (fr) |
MA (1) | MA37808A1 (fr) |
MX (1) | MX2015000101A (fr) |
PH (1) | PH12015500179A1 (fr) |
RU (1) | RU2015102278A (fr) |
SG (1) | SG11201408770RA (fr) |
WO (1) | WO2014004884A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201692091A1 (ru) | 2014-04-18 | 2017-04-28 | Милленниум Фармасьютикалз, Инк. | Хиноксалиновые соединения и их применение |
US20170183297A1 (en) * | 2014-05-22 | 2017-06-29 | The University Of Sydney | Omega-3 analogues |
CA2974078A1 (fr) | 2015-01-20 | 2016-07-28 | Millennium Pharmaceuticals, Inc. | Composes quinazoline et quinoleine, et utilisations de ceux-ci |
DK3594343T3 (da) * | 2015-07-23 | 2021-06-28 | Inst Curie | Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft |
FR3047552A1 (fr) * | 2016-02-05 | 2017-08-11 | Air Liquide | Introduction optimisee d'un courant refrigerant mixte diphasique dans un procede de liquefaction de gaz naturel |
JPWO2017170826A1 (ja) * | 2016-03-30 | 2019-02-14 | 味の素株式会社 | グルカゴン様ペプチド−1受容体作用増強活性を有する化合物 |
KR101869794B1 (ko) * | 2016-07-20 | 2018-06-21 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
US10683387B2 (en) | 2016-10-04 | 2020-06-16 | Massachusetts Institute Of Technology | Bottlebrush copolymers and uses thereof |
WO2019006425A1 (fr) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | Agents d'imagerie de polymères en étoile à bras de brosse et leurs utilisations |
JP7187048B2 (ja) | 2017-06-30 | 2022-12-12 | マサチューセッツ インスティテュート オブ テクノロジー | 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用 |
KR101937126B1 (ko) * | 2018-06-15 | 2019-01-10 | 연세대학교 산학협력단 | 내성암, 재발암 또는 전이암의 예방 또는 치료용 약학 조성물 |
WO2020037236A1 (fr) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Polymères dégradables d'un éther de silyle cyclique et utilisations associées |
CN114096243A (zh) * | 2018-10-22 | 2022-02-25 | 耶鲁大学 | 鉴定PPM1D突变作为NAMPTi敏感性的新型生物标志物 |
US20210113701A1 (en) * | 2019-10-16 | 2021-04-22 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
US7253193B2 (en) * | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
EP1507760B1 (fr) * | 2002-05-17 | 2007-08-01 | Leo Pharma A/S | Promedicaments de cyanoguanidine |
JP5688367B2 (ja) * | 2008-08-29 | 2015-03-25 | トポターゲット・アクティーゼルスカブTopoTarget A/S | 新規なウレアおよびチオウレア誘導体 |
CA2791680A1 (fr) * | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Composes et utilisations therapeutiques associees |
CA2809391A1 (fr) * | 2010-09-03 | 2012-03-08 | Genentech, Inc. | Derives de 4-{[(pyridin-3-yl-methyl)aminocarbonyl]amino}benzene-sulfone en tant qu'inhibiteurs de nampt utilises dans le traitement de maladies telles que le cancer |
-
2013
- 2013-06-27 MA MA37808A patent/MA37808A1/fr unknown
- 2013-06-27 IN IN240KON2015 patent/IN2015KN00240A/en unknown
- 2013-06-27 KR KR20157002268A patent/KR20150024932A/ko not_active Application Discontinuation
- 2013-06-27 MX MX2015000101A patent/MX2015000101A/es unknown
- 2013-06-27 WO PCT/US2013/048274 patent/WO2014004884A1/fr active Application Filing
- 2013-06-27 RU RU2015102278A patent/RU2015102278A/ru not_active Application Discontinuation
- 2013-06-27 AU AU2013284487A patent/AU2013284487A1/en not_active Abandoned
- 2013-06-27 JP JP2015520521A patent/JP2015522028A/ja active Pending
- 2013-06-27 BR BR112014032917A patent/BR112014032917A2/pt not_active IP Right Cessation
- 2013-06-27 SG SG11201408770RA patent/SG11201408770RA/en unknown
- 2013-06-27 CN CN201380045302.4A patent/CN104768931A/zh active Pending
- 2013-06-27 EP EP13810056.5A patent/EP2867209A4/fr not_active Withdrawn
-
2014
- 2014-12-24 US US14/582,641 patent/US20150344426A1/en not_active Abandoned
- 2014-12-28 IL IL236499A patent/IL236499A0/en unknown
- 2014-12-29 CL CL2014003560A patent/CL2014003560A1/es unknown
-
2015
- 2015-01-27 PH PH12015500179A patent/PH12015500179A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12015500179A1 (en) | 2015-04-06 |
KR20150024932A (ko) | 2015-03-09 |
IN2015KN00240A (fr) | 2015-06-12 |
JP2015522028A (ja) | 2015-08-03 |
US20150344426A1 (en) | 2015-12-03 |
RU2015102278A (ru) | 2016-08-20 |
IL236499A0 (en) | 2015-02-26 |
WO2014004884A1 (fr) | 2014-01-03 |
MX2015000101A (es) | 2015-06-22 |
AU2013284487A1 (en) | 2015-02-19 |
EP2867209A4 (fr) | 2015-11-25 |
SG11201408770RA (en) | 2015-01-29 |
BR112014032917A2 (pt) | 2017-06-27 |
CN104768931A (zh) | 2015-07-08 |
CL2014003560A1 (es) | 2015-11-27 |
EP2867209A1 (fr) | 2015-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA37808A1 (fr) | Composés et leurs utilisations thérapeutiques | |
MA38276B1 (fr) | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. | |
EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
BR112015007985A2 (pt) | compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados | |
MA38396A1 (fr) | Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit | |
CY1118311T1 (el) | Παραγωγα νιτροκατεχολης ως αναστολεις comt που χορηγουνται με ειδικη αγωγη δοσολογιας | |
MA32300B1 (fr) | Anticorps anti-facteur d humanises et utilisations de ceux-ci | |
EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
EA201491606A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
EA201100910A1 (ru) | Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих | |
BR112012016543A2 (pt) | Tratamento com vb-201 | |
BR112016012258A2 (pt) | Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
MA34670B1 (fr) | Inhibiteurs de l'apoptose et leurs utilisations | |
MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
BR112016023450A2 (pt) | uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce | |
FR2981936B1 (fr) | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. | |
WO2008076824A3 (fr) | Peptides utilisées à des fins thérapeutiques et diagnostiques |